+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
Healthy Volunteers
ID05580458

Safety and Immune Response Evaluation of Shingrix Vaccine in Adults with HIV and Healthy Volunteers

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-11-03

225

Participants Needed

1

Research Sites

34 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and immune response of the Shingrix vaccine in people with HIV aged 18 years and older, as well as in healthy adults aged 50 years and older. The study aims to understand how the vaccine affects immune function in these groups, particularly focusing on differences in immune response based on CD4 cell counts and age. This phase 12 open-label trial includes monitoring of adverse events and comparison between people with HIV and healthy volunteers. Participants will receive two doses of Shingrix vaccine administered by intramuscular injection in the upper arm, spaced about 2 months apart. Blood samples will be collected before each dose and at follow-up visits at 3 and 12 months after the first dose. Additional procedures include rectal swabs for microbiome analysis and optional apheresis to collect white blood cells. Participants will also use a 28-day memory tool to record symptoms and participate in up to four phone calls discussing vaccine side effects. Participants will attend at least four clinic visits over one year for physical exams, blood and urine tests, and safety monitoring. Researchers will evaluate immune responses through antibody measurements and T-cell assays, as well as track safety by assessing adverse events. The study includes ongoing monitoring of viral load in people with HIV and collects detailed health information to correlate with vaccine response. Total participation lasts about one year with follow-up visits to assess long-term effects.

CONDITIONS

Brief Title

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Research Team

M

Maura M Manion, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here